Serge Jabbour

15PUBLICATIONS
16CO-AUTHORS
Free radical chemistryMajor global burdens of diseasePharmaceutical delivery technologiesBehavioural epidemiologyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Apr 17, 2025
Heterozygous Hereditary Vitamin D-Dependent Rickets Type 2A (VDDR2A) in a Patient Presenting With Pseudoarthrosis.

Risa Goldberg, Gunjan Umarji, Serge Jabbour

|Sep 23, 2022
Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis.

Jean-Etienne Poirrier, Juliana L Meyers, Saurabh P Nagar

|Mar 03, 2022
Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice.

Kamlesh Khunti, Serge Jabbour, Xavier Cos

|Aug 21, 2020
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.

Serge A Jabbour, Juan P Frías, Azazuddin Ahmed

|Feb 01, 2020
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.

Tina Vilsbøll, Ella Ekholm, Eva Johnsson

|Nov 07, 2019
Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.

Amalia Gastaldelli, Enrico Repetto, Cristian Guja

Pageof 3

Frequent Collaborators

6 joint publications

Cristian Guja

5 joint publications

Juan P Frías

3 joint publications

Marcus Lind

2 joint publications

Ele Ferrannini